Related search

Letter: Is There a Role for Infliximab Biosimilar in Patients With Inflammatory Bowel Disease With Secondary Loss of Response to Infliximab Innovator?

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Infliximab Versus Adalimumab in Patients With Biologic-Naïve Crohn’s Disease: Is the Difference Real?

Digestive Diseases and Sciences
PhysiologyGastroenterology
2018English

Mechanisms That Mediate the Development of Fibrosis in Patients With Crohnʼs Disease

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2014English

Low-Dose Glucocorticoid Therapy Decreases Risk for Treatment-Limiting Infusion Reaction to Infliximab in Patients With Rheumatoid Arthritis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2007English

Neuropathy in Parkinson’s Disease Patients With Intestinal Levodopa Infusion Versus Oral Drugs

PLoS ONE
Multidisciplinary
2013English

Increase in Methotrexate Dose in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Infliximab

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2005English

Efficacy of Infliximab Biosimilars in Patients With Crohn's Disease

The Lancet
Medicine
2017English

Cisatracurium Dose–response Relationship in Patients With Chronic Liver Disease

Egyptian Journal of Anaesthesia
AnesthesiologyPain Medicine
2014English

Risk Factors for Metabolic Bone Disease in Crohnʼs Disease Patients

Inflammatory Bowel Diseases
AllergyImmunologyGastroenterology
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy